Codexis Inc Total Liabilities
Codexis Inc total liabilities. Based on the latest financial reports, Codexis Inc (CDXS) has total liabilities worth $85.42 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CDXS financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Codexis Inc (2006–2024)
Total liabilities of Codexis Inc from 2006 to 2024. This chart illustrates how Codexis Inc's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Codexis Inc to see how much of total assets are deployed in long-term investments.
Codexis Inc Competitors by Total Liabilities
The table below lists competitors of Codexis Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Smartphoto Group NV
BR:SMAR
|
Belgium | €36.85 Million |
|
SkyWorld Development Berhad
KLSE:5315
|
Malaysia | RM1.23 Billion |
|
TDG Gold Corp
V:TDG
|
Canada | CA$6.37 Million |
|
Orient Technologies Limited
NSE:ORIENTTECH
|
India | Rs2.33 Billion |
|
SOTKAMO SILVER AB NAM.
F:VSO
|
Germany | €359.70 Million |
|
My Humble House Hospitality Management Consulting Co Ltd
TW:2739
|
Taiwan | NT$10.22 Billion |
|
Han Chang Pape
KO:009460
|
Korea | ₩207.27 Billion |
|
Indústrias Romi S.A
SA:ROMI3
|
Brazil | R$1.35 Billion |
Liability Composition Analysis (2006–2024)
This chart breaks down Codexis Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Codexis Inc.
Liquidity & Leverage Metrics
Codexis Inc Total Liabilities Ratios Explained
Codexis Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.69 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Codexis Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Codexis Inc (2006–2024)
The table below shows the annual total liabilities of Codexis Inc from 2006 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $82.08 Million | +64.35% |
| 2023-12-31 | $49.95 Million | -52.70% |
| 2022-12-31 | $105.60 Million | +28.79% |
| 2021-12-31 | $81.99 Million | +59.07% |
| 2020-12-31 | $51.54 Million | +18.34% |
| 2019-12-31 | $43.56 Million | +98.19% |
| 2018-12-31 | $21.98 Million | -24.42% |
| 2017-12-31 | $29.08 Million | +75.71% |
| 2016-12-31 | $16.55 Million | -23.98% |
| 2015-12-31 | $21.77 Million | -0.20% |
| 2014-12-31 | $21.81 Million | +25.66% |
| 2013-12-31 | $17.36 Million | -19.36% |
| 2012-12-31 | $21.52 Million | -35.23% |
| 2011-12-31 | $33.23 Million | -2.08% |
| 2010-12-31 | $33.94 Million | -45.44% |
| 2009-12-31 | $62.20 Million | -68.90% |
| 2008-12-31 | $200.01 Million | -0.50% |
| 2007-12-31 | $201.01 Million | +102.17% |
| 2006-12-31 | $99.42 Million | -- |
About Codexis Inc
Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the … Read more